Companies House 06384429 2025-12-31 2025-12-31 2025-01-01 false iso4217:GBP xbrli:pure 06384429 2024-01-01 2024-12-31 06384429 2025-12-31 06384429 2025-01-01 2025-12-31 06384429 2024-12-31 06384429 curr:PoundSterling 2025-01-01 2025-12-31 06384429 uk-bus:CompanyLimitedByGuarantee 2025-01-01 2025-12-31 06384429 uk-bus:FRS102 2025-01-01 2025-12-31 06384429 uk-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06384429 uk-bus:FullAccounts 2025-01-01 2025-12-31 06384429 uk-bus:RegisteredOffice 2025-01-01 2025-12-31 06384429 uk-bus:Director1 2025-01-01 2025-12-31 06384429 uk-bus:Director2 2025-01-01 2025-12-31 06384429 uk-bus:Director3 2025-01-01 2025-12-31 06384429 uk-bus:Director4 2025-01-01 2025-12-31 06384429 uk-bus:Director5 2025-01-01 2025-12-31 06384429 uk-bus:Director6 2025-01-01 2025-12-31 06384429 uk-bus:Director7 2025-01-01 2025-12-31 06384429 uk-bus:Director8 2025-01-01 2025-12-31 06384429 uk-bus:Director9 2025-01-01 2025-12-31 06384429 uk-bus:Director10 2025-01-01 2025-12-31 06384429 uk-bus:Director11 2025-01-01 2025-12-31 06384429 uk-bus:Director12 2025-01-01 2025-12-31 06384429 uk-bus:Director13 2025-01-01 2025-12-31 06384429 uk-bus:Director14 2025-01-01 2025-12-31 06384429 uk-bus:Director15 2025-01-01 2025-12-31 06384429 uk-bus:Director16 2025-01-01 2025-12-31 06384429 uk-bus:Director17 2025-01-01 2025-12-31 06384429 uk-bus:Director18 2025-01-01 2025-12-31 06384429 uk-bus:Director19 2025-01-01 2025-12-31 06384429 uk-bus:Director20 2025-01-01 2025-12-31 06384429 uk-bus:Director21 2025-01-01 2025-12-31 06384429 uk-bus:CompanySecretary1 2025-01-01 2025-12-31 06384429 core:AfterOneYear 2025-12-31 06384429 core:AfterOneYear 2024-12-31 06384429 core:WithinOneYear 2025-12-31 06384429 core:WithinOneYear 2024-12-31 06384429 core:WithinOneYear 2025-01-01 2025-12-31 06384429 core:AfterOneYear 2025-12-31 06384429 core:AfterOneYear 2024-12-31 06384429 core:AfterOneYear 2025-01-01 2025-12-31 06384429 core:ShareCapital 2025-12-31 06384429 core:ShareCapital 2024-12-31 06384429 core:SharePremium 2025-12-31 06384429 core:SharePremium 2024-12-31 06384429 core:OtherReservesSubtotal 2025-12-31 06384429 core:OtherReservesSubtotal 2024-12-31 06384429 core:RevaluationReserve 2025-12-31 06384429 core:RevaluationReserve 2024-12-31 06384429 core:RetainedEarningsAccumulatedLosses 2025-12-31 06384429 core:RetainedEarningsAccumulatedLosses 2024-12-31 06384429 1 2025-01-01 2025-12-31 06384429 2 2025-01-01 2025-12-31 06384429 3 2025-01-01 2025-12-31 06384429 core:LandBuildings 2025-01-01 2025-12-31 06384429 core:LandBuildings 2025-12-31 06384429 core:LandBuildings 2024-01-01 2024-12-31 06384429 core:LandBuildings 2024-12-31 06384429 core:PlantMachinery 2025-01-01 2025-12-31 06384429 core:PlantMachinery 2025-12-31 06384429 core:PlantMachinery 2024-01-01 2024-12-31 06384429 core:PlantMachinery 2024-12-31 06384429 core:FurnitureFittingsToolsEquipment 2025-01-01 2025-12-31 06384429 core:FurnitureFittingsToolsEquipment 2025-12-31 06384429 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 06384429 core:FurnitureFittingsToolsEquipment 2024-12-31 06384429 core:OfficeEquipment 2025-01-01 2025-12-31 06384429 core:OfficeEquipment 2025-12-31 06384429 core:OfficeEquipment 2024-01-01 2024-12-31 06384429 core:OfficeEquipment 2024-12-31 06384429 core:Vehicles 2025-01-01 2025-12-31 06384429 core:Vehicles 2025-12-31 06384429 core:Vehicles 2024-01-01 2024-12-31 06384429 core:Vehicles 2024-12-31 06384429 core:NetGoodwill 2025-01-01 2025-12-31 06384429 core:NetGoodwill 2025-12-31 06384429 core:NetGoodwill 2024-01-01 2024-12-31 06384429 core:NetGoodwill 2024-12-31 06384429 core:IntangibleAssetsOtherThanGoodwill 2025-01-01 2025-12-31 06384429 core:IntangibleAssetsOtherThanGoodwill 2025-12-31 06384429 core:IntangibleAssetsOtherThanGoodwill 2024-01-01 2024-12-31 06384429 core:IntangibleAssetsOtherThanGoodwill 2024-12-31

# EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

## Company limited by guarantee

## Company Registration Number:
06384429 (England and Wales)

## Unaudited statutory accounts for the year ended 31 December 2025

## Period of accounts

## Start date: 1 January 2025

## End date: 31 December 2025

# EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

## Contents of the Financial Statements

for the Period Ended 31 December 2025

Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

## Balance sheet

As at 31 December 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Current assets
Cash at bank and in hand: |  | 2,533 | 498
Total current assets: |  | 2,533 | 498
Creditors: amounts falling due within one year: | 3 | ( 2,985 ) | ( 1,020 )
Net current assets (liabilities): |  | (452) | (522)
Total assets less current liabilities: |  | (452) | ( 522)
Total net assets (liabilities): |  | (452) | (522)
Members' funds
Profit and loss account: |  | (452) | ( 522)
Total members' funds: |  | ( 452) | (522)

The notes form part of these financial statements

# EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

## Balance sheet statements

For the year ending 31 December 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 13 July 2026
and signed on behalf of the board by:

Name: M P Isles
Status: Director

The notes form part of these financial statements

# EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

## Notes to the Financial Statements

for the Period Ended 31 December 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

# EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

## Notes to the Financial Statements

for the Period Ended 31 December 2025

- ## 2. Employees

  | 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 1 | 1

# EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 3. Creditors: amounts falling due within one year note

| 2025 | 2024
--- | --- | ---
| £ | £
Other creditors | 2,985 | 1,020
Total | 2,985 | 1,020

# COMMUNITY INTEREST ANNUAL REPORT

### EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

### Company Number: 06384429 (England and Wales)

### Year Ending: 31 December 2025

Company activities and impact

The EAASM has had another successful year and has fulfilled its CIC obligations admirably and the Summer newsletter highlights this and can be seen at www.eaasm.eu. The EAASM continues to be actively involved with the EU Parliament and attends relevant meetings and contributes to healthcare debates in the Parliament bringing together MEPs, Commission and the Council. The EAASM continues to support the objectives and recommendations of the EU Healthcare Coalition to which it is a partner. Whilst the DOTPharmacy NABP top level domain name initiative largely resides with the ASOP EU Company, the EAASM continues to support this important activity. Working closely with an NABP colleague, we have made great efforts to raise awareness about this top level domain name amongst pharmacy bodies in the UK and beyond which provides a secure sefehaven for patients to obtain their prescription medicines online. The EAASM continues to support the objectives of the Capacity Enhancing Innovation working group (CEI). This is a collaborative initiative focused on showcasing innovative technologies and solutions as complementary approaches to tackling critical workforce shortages in European healthcare systems, By uniting a diverse range of healthcare stakeholders, the group promotes the adoption of practical, scalable innovations to support care delivery and inform forward-looking health policy. The EAASM has attended the meetings organised by the CEI and EU Health Coalition.

Consultation with stakeholders

The above mentioned topics and activities have been communicated to its members and the EAASM Board (a board meeting was held on 12 August 2025) to review and agree the above activities and concomitant objectives. Communication regarding funding takes place with its members every year.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
17 July 2026

And signed on behalf of the board by:
Name: M P Isles
Status: Director